The Biomembrane Institute

Fred Hutchinson Cancer Center

Seikagaku Corporation

Cell Therapeutics, Inc.

Oncomembrane, Inc.

Other

Glyconex, Inc.

Jichi Medical School

Sen-itiroh Hakomori

Edward D Nudelman

Yasuyuki Igarashi

Steven B Levery

Kazuko Handa

Mark R Stroud

Mahammad N Ahmad

Henrik Clausen

Anil Singhal

Hirofumi Okoshi

Hidemitsu Matsuura

Yasuo Fukushi

Mary Ellen Salyan

Fumi-ichiro Yamamoto

Thayer White

Khalid Sadozai

Jerry Ting

Liahng-Yirn Liu

Shu-Yen Chang

Tong-Hsuan Chang

Tatsushi Toyokuni

Walter E Stamm

Ann Stapleton

Mei-Chun Yang

Hisao Nojiri

Ying-Jin Chen

Hideki Ohta

Yutaka Yatomi

Jaw-Yuan Wen

Naoya Kojima

Tsai-Hsia Hong

Michiro Otaka

Kazuo Muroi

Toshio Suda

Human antibodies and antigen-binding portions of those antibodies that specifically bind extended Type I chain glycosphingolipids are provided.

Anti-extended type I glycosphingolipid antibody, derivatives thereof and use

Compositions and methods for diagnosing, treating and preventing recurrent urinary tract infections relate to the detection and use of globosides, such as disialosyl galactosyl-globoside (DSGG) and sialosyl galactosyl-globoside (SGG), and stabilized forms thereof, such as those wherein sialic acid is replaced by KDN

Compositions for treating Escherichia coli urinary tract infections

A variety of compounds are provided which are useful as immunogens and as tumor markers. The present invention discloses methods relating to the detection of cancer. Extended forms of the lacto-series type 1 chain are shown to be present in various cancer tissues. The present invention also provides a cell line and the monoclonal antibody produced therefrom. Such an antibody has a number of uses, including in diagnostic or therapeutic methods.

Extended type 1 chain glycosphingolipids as tumor-associated antigens

An unbranched polylactosamine comprising at least 6 monosaccharides and having terminal .alpha.2.fwdarw.3 sialylation and internal .alpha.1.fwdarw.3 fucosylation at various N-acetylglucosamine residues except for solely at the penultimate N-acetylglucosamine residue.

Carbohydrate ligands (myelorollin) that cause E-selectin dependent cell

A variety of compounds are provided which are usefdl as immunogens and as tumor markers. The present invention discloses methods relating to the detection of cancer. Extended forms of the lacto-series type 1 chain are shown to be present in various cancer tissues. The present invention also provides a cell line and the monoclonal antibody produced therefrom. Such an antibody has a number of uses, including in diagnostic or therapeutic methods.

Alk-1-enyl glycerol derivatives and method of preparing same. The derivatives stimulate cell and tissue growth.

Growth stimulating factors

The invention relates to antibodies that specifically bind a myelorollin comprising an unbranched polylactosamine comprising at least 10 monosaccharides and having terminal .alpha.2.fwdarw.3 sialylation and internal .alpha.1.fwdarw.3 fucosylation at various N-acetylglucosamine residues except the penultimate N-acetylglucosamine residue. The invention also relates to a method of using such antibodies to inhibit E-selectin-dependent rolling of a cell on another cell, wherein one of the cells expresses a myelorollin that binds the antibodies.

Antibodies that bind novel carbohydrate ligands (myelorollins) that

An isolated plasmalopsychosine selected from the group consisting of compound A and compound B: ##STR1## wherein n1 is 0-50 or an isolated synthetic plasmalocerebroside selected from the group consisting of compound C and compound D: ##STR2## wherein n2 and n3 each is 0-50.

Plasmalopsychosines and plasmalocerebrosides

A method of detecting sphingosines and platelet activation is disclosed.

Method for quantifying sphingosine and for diagnosing platelet activation

A method of producing monoclonal antibodies that bind to tumor-associated gangliosides, the method comprising: (1) immunizing a host with tumor cells; (2) boosting the host with a suspension comprising a mixture of tumor cell membrane and at least one purified lactonized tumor-associated ganglioside; (3) boosting the host with an immunogen comprising a lactone of a tumor associated ganglioside adsorbed on or incorporated into a carrier; (4) fusing immunized cells from the host with myeloma cells to form hybridoma cells; (5) selecting hybridoma cells that produce antibody that binds to the ganglioside of step (3); (6) culturing the selected hybridoma cells; and (7) recovering the antibody.

Blood treatment method

The genes defining the ABO histo-blood groups are disclosed. Methods for identification of histo-blood group ABO status are provided. The methods include the use of DNA probes or size separation of DNA fragments unique to a blood group status. The present invention also discloses DNA constructs, recombinant methods for providing histo-blood glycosyltransferases, methods for tumor suppression, purified histo-blood group glycosyltransferases, and antibodies produced therefrom which bind to protein epitopes.

ABO genotyping

O-glycosylation and O-glycosylation extension inhibitors influence selectin-dependent interactions between cells and between cells and platelets.

Method for inhibiting selectin-dependent adhesion of leukocytes and

The invention relates to a novel compound, compositions and medicaments thereof and a method of inhibiting cell proliferation, platelet aggregation (induced by various factors), and inhibiting malignant phenotypes of tumor cells such as those having a metastatic property, using said compound, composition or medicament. N,N,N-trimethylsphingosine shows superior cell proliferation inhibitory and anti-metastatic activity over related compounds.

Method of preparing N,N,N-trimethylsphingosine

Growing community of inventors

Mercer Island, WA, United States of America

Sen-itiroh Hakomori